Comparison of efficacy and safety of entecavir and tenofovir in the treatment of patients with HBeAg-positive chronic hepatitis B / 中国基层医药

ABSTRACT

Objective:To compare the efficacy and safety of entecavir and tenofovir in the treatment of patients with HBV E antigen (HBeAg)-positive chronic hepatitis B (CHB).Methods:A total of 158 CHB patients admitted in Chengde Central Hospital from January 2017 to December 2018 were divided into entecavir (ETV) group and tenofovir (TDF) group by random digital table method, with 79 cases in each group.The HBeAg conversion rate, HBV DNA negative conversion rate and serum alanine transaminase (ALT) recurrence rate in two groups at 6 months and 12 months after treatment were compared, and the incidence of adverse reactions was recorded.Results:After 6 and 12 months of treatment, the negative rates of HBV DNA in TDF group(59.49%, 72.15%) were significantly higher than those in ETV group(44.30%, 55.70%), and the differences between the two groups were statistically significant (χ 2=4.232, 6.334, all P<0.05). The differences of ALT recurrence rate and HBeAg conversion rate between the two groups were not statistically significant (χ 2=0.328, 0.037, χ 2=0.767, 0.694, all P>0.05). The total effective rates in the two groups were 75.94% and 59.49%, respectively.The incidence of adverse reactions in TDF group was 7.59% (6/79), which in ETV group was 11.39% (9/79), the difference between the two groups was not statistically significant (χ 2=0.558, P>0.05). Conclusion:TDF is superior to ETV in inhibiting HBV replication and is similar in security.